Safety of direct antiviral agents in the management of hepatitis C

Expert Opinion on Drug Safety

Volumn 15, Issue 12, 2016, Pages 1643-1652

  El Kassas, Mohamed ^a   Elbaz, Tamer ^b   Hafez, Enas ^c   Esmat, Gamal ^b  

^a Helwan University   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c Clinical Pharmacy Unit   (Egypt)

Author keywords

Direct antiviral agents; drug interactions; hepatitis C (HCV); safety; side effects

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; DACLATASVIR; INTERFERON; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ANEMIA; ARTHRALGIA; ASTHENIA; CELLULITIS; CHOLELITHIASIS; COMPRESSION FRACTURE; DELIRIUM; DIARRHEA; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INTERACTION; DRUG SAFETY; DYSGEUSIA; DYSPNEA; FATIGUE; GASTROENTERITIS; HAND FRACTURE; HEADACHE; HEMOLYSIS; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; INSOMNIA; MULTICENTER STUDY (TOPIC); MYALGIA; NAUSEA; NEUTROPENIA; PANCREATITIS; PEPTIC ULCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PNEUMONIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESPIRATORY TRACT INFECTION; RETINA TEAR; REVIEW; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SUICIDAL IDEATION; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRUS REPLICATION; VISUAL IMPAIRMENT; ANIMAL; DRUG EFFECTS; HEPACIVIRUS;

ANIMALS; ANTIVIRAL AGENTS; DRUG INTERACTIONS; HEPACIVIRUS; HEPATITIS C; HUMANS; VIRUS REPLICATION;

EID: 84996550853     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2017.1240781     Document Type: Review

References (61)

1. Jazwinski A, Muir A., Direct-acting antiviral medications for chronic hepatitis C virus infection. Gastroenterol Hepatol (N Y). 2011;7(3):154–162.
2. Asselah T, Marcellin P. New direct-acting antivirals’ combination for the treatment of chronic hepatitis C. Liver Int. 2011;31(1):68–77.
3. Calleja JL, Pascasio JM, Ruiz-Antorán B, et al. Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis:SVRw12 analysis. Liver Int. 2015;35(1):90–100.
4. Lontok E, Harrington P, Howe A, et al. Hepatitis C virus drug resistance–associated substitutions:state of the art. Hepatology. 2015;62(5):1623–1632.
5. Paolucci S, Fiorina L, Piralla A, et al. Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients. Virol J. 2012;9:245.
6. Burger D, Back D, Buggisch P, et al. Clinical management of drug-drug interactions in HCV therapy:challenges and solutions. J Hepatol. 2013;58:792–800.
7. Kiser JJ, Burton JRJ, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10(10):596–606.
8. Kwo PY. Boceprevir:a novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infection. Therap Adv Gastroenterol. 2012;5(3):179–188.
9. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199–236.
10. Poordad F, McCone J, Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195–1206.
11. Lens S, Calleja JL, Campillo A, et al. Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C. World J Gastroenterol. 2015 May 7;21(17):5421–5426.
12. Hézode C. Boceprevir and telaprevir for the treatment of chronic hepatitis C:safety management inclinical practice. Liver Int. 2012;32(1):32–38.
13. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–1217.
14. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–2416.
15. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–2428.
16. Ramachandran P, Fraser A, Agarwal K, et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther. 2012;35(6):647–662.
17. Torii H, Sueki H, Kumada H, et al. Dermatological side-effects of telaprevir-based triple therapy for chronic hepatitis C in phase III trials in Japan. J Dermatol. 2013;40(8):587–595.
18. Hézode C1, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French early access programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol. 2013;59(3):434–441.
19. Wilby KJ, Greanya ED, Ford JA, et al. A review of drug interactions with boceprevir and telaprevir:implications for HIV and transplant patients. Ann Hepatol. 2012;11(2):179–185.
20. Center for Drug Evaluation and Research. Application number:NDA 205123/S-008. Reference ID:3718944 [cited 2016 Jan20]. Available from:www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205123Orig1s008.pdf
21. INITIAL TREATMENT OF HCV INFECTION. AASLD. Published on recommendations for testing, managing, and treating hepatitis C [cited 2016 Jan20]. Available from:www.hcvguidelines.org/full-report/initial-treatment-hcv-infection• The most important practical guidelines in HCV management field.
22. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77–87.
23. Poveda E, Wyles DL, Mena A, et al. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res. 2014;108:181–191.
24. Elbaz T, El-Kassas M, Esmat G. New era for management of chronic hepatitis C virus using direct antiviral agents:a review. J Adv Res. 2015;6(3):301–310.
25. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non responders to pegylated interferon and ribavirin and treatment naïve patients:the COSMOS randomised study. Lancet. 2014;384(9956):1756–1765.
26. Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy:a phase 3 trial. Gastroenterology. 2014;146(7):1669–1679.e3.
27. FDA approves Sovaldi for chronic hepatitis C. FDA NEWS RELEASE [cited 2016 Jan20]. Available from:http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377888.htm
28. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867–1877.
29. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368(1):34–44.
30. Supplementary Appendix to Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–1887 [cited 2016 Jan19]. Available from:www.nejm.org/doi/suppl/10.1056/NEJMoa1214853/suppl_file/nejmoa1214853_appendix.pdf
31. Younossi ZM, Stepanova M, Zeuzem S, et al. Patient reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin:the VALENCE study. J Hepatol. 2014;61(2):228–234.
32. Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2):a multicentre, open-label, non-randomised,phase 3 study. Lancet. 2015;385(9973):1098–1106.
33. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–1887.
34. Doss W, Shiha G, Hassany M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol. 2015;63(3):581–585.
35. Svarovskaia ES, Dvory-Sobol H, Parkin N, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus–infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis. 2014 Dec 15;59(12):1666–1674.
36. Sofosbuvir:HIGHLIGHTS OF PRESCRIBING INFORMATION [cited 2016 Jan19]. Available from:www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf
37. Hundemer GL, Sise ME, Wisocky J, et al. Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infect Dis (Lond). 2015;47(12):924–929.
38. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection:ALLY-3 phase III study. Hepatology. 2015;61(4):1127–1135.
39. DAKLINZA AK(daclatasvir):HIGHLIGHTS OF PRESCRIBING INFORMATION [cited 2016 Jan19]. Available from:www.accessdata.fda.gov/drugsatfda_docs/label/2015/206843Orig1s000lbl.pdf
40. DRUG INTERACTIONS WITH NEW/INVESTIGATIONAL HEPATITIS C NS5A INHIBITORS. Academic copyright:Alice Tseng, Pharm.D., FCSHP, AAHIVP, Toronto General Hospital and Pierre Giguere, M.Sc.Phm., The Ottawa Hospital www.hcvdruginfo.ca. 2015 May 28 [cited 2016 Jan 19]. Available from Hepatitis C New/Investigational NS5A Inhibitors:www.hcvdruginfo.ca/tables/html
41. Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients co-infected with HIV-1. N Engl J Med. 2015;373(8):714–725.
42. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–221.
43. Link JO, Taylor JG, Xu L, et al. Discovery of ledipasvir (GS-5885):a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014 Mar 13;57(5):2033–2046.
44. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR):an open-label, randomised, phase 2trial. Lancet. 2014;383(9916):515–523.
45. Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. Jama. 2015 Mar 24-31;313(12):1232–1239.
46. Townsend K, Petersen T, Gordon LA, et al. Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir. Aids. 2016;30(2):261–266.
47. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014 May 15;370(20):1889–1898.
48. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014 Apr 17;370(16):1483–1493.
49. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–1888.
50. Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):705–713.
51. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and Sofosbuvir Plus Ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015 Sep;149(3):649–659.
52. Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease:a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16(6):685–697.
53. Harvoni™a(ledipasvir and sofosbuvir):HIGHLIGHTS OF PRESCRIBING INFORMATION [cited 2016 Jan19]. Available from:www.accessdata.fda.gov/drugsatfda_docs/label/2014/205834s000lbl.pdf
54. Raedler LA. Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir tablets; Dasabuvir tablets):all-oral fixed combination approved for genotype 1 chronic hepatitis C infection. Am Health Drug Benefits. 2015;8(Spec Feature):142–147.
55. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24;370(17):1594–1603.
56. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604–1614.
57. Andreone P, Colombo MG, Enejosa JV, et al. ABT 450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(2):359–365.e1.
58. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r–ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014 May 22;370(21):1983–1992.
59. Poordad F, Hezode C, Trinh R, et al. ABT-450/r, ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973–1982.
60. VIEKIRA PAK (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), co-packaged for oral use:HIGHLIGHTS OF PRESCRIBING INFORMATION [cited 2016 Jan19]. Available from:www.accessdata.fda.gov/drugsatfda_docs/label/2015/206619s008lbl.pdf
61. Smith MA, Lim A. Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection. Drug Des Devel Ther. 2015 Nov 13;9:6083–6094.